Pediatrix Q3 adjusted EPS $0.44, revenue $511M; reaffirms FY 2024 EBITDA guidance $205-215M

Pediatrix Medical Group, Inc.

2024-Q3 EPS reported -$1.56 revenue$1,510,555,000

Net revenue $511M, up from $506.6M YoY; same-unit revenue grew 5.2% (reimbursement +3.4%, volume +1.8%).
GAAP EPS $0.23, down from $0.26 YoY; Adjusted EPS $0.44 vs $0.32; Adjusted EBITDA $60M vs $50.4M.
Exiting almost all office-based practices (except maternal-fetal medicine); expects ~$30M annualized EBITDA benefit by year-end.
Cash from operations $95.7M; total debt $619M, no revolver borrowings; completed hybrid RCM transition.
FY 2024 Adjusted EBITDA guidance $205-215M, implying Q4 roughly $50-60M based on YTD result of $155.3M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.